Engineering receptor-binding domain and heptad repeat domains towards the development of multi-epitopes oral vaccines against SARS-CoV-2 variants
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0306111 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Nur Farhanah Arshad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Faculty of Applied Sciences, UCSI University, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19 Vaccines, Epitopes, B-Lymphocyte, Epitopes, T-Lymphocyte. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Higher Education, Malaysia, UCSI University https://www.ucsiuniversity.edu.my/about-us/research.
Abstract (Originalsprache)
The inability of existing vaccines to cope with the mutation rate has highlighted the need for effective preventative strategies for COVID-19. Through the secretion of immunoglobulin A, mucosal delivery of vaccines can effectively stimulate mucosal immunity for better protection against SARS-CoV-2 infection. In this study, various immunoinformatic tools were used to design a multi-epitope oral vaccine against SARS-CoV-2 based on its receptor-binding domain (RBD) and heptad repeat (HR) domains. T and B lymphocyte epitopes were initially predicted from the RBD and HR domains of SARS-CoV-2, and potential antigenic, immunogenic, non-allergenic, and non-toxic epitopes were identified. Epitopes that are highly conserved and have no significant similarity to human proteome were selected. The epitopes were joined with appropriate linkers, and an adjuvant was added to enhance the vaccine efficacy. The vaccine 3D structure constructs were docked with toll-like receptor 4 (TLR-4) and TLR1-TLR2, and the binding affinity was calculated. The designed multi-epitope vaccine construct (MEVC) consisted of 33 antigenic T and B lymphocyte epitopes. The results of molecular dockings and free binding energies confirmed that the MEVC effectively binds to TLR molecules, and the complexes were stable. The results suggested that the designed MEVC is a potentially safe and effective oral vaccine against SARS-CoV-2. This in silico study presents a novel approach for creating an oral multi-epitope vaccine against the rapidly evolving SARS-CoV-2 variants. These findings offer valuable insights for developing an effective strategy to combat COVID-19. Further preclinical and clinical studies are required to confirm the efficacy of the MEVC vaccine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, Faculty of Applied Sciences, UCSI University, Kuala Lumpur, Malaysia.
- Department of Biological Sciences and Biotechnology, Faculty of Science & Technology, Universiti Kebangsaan Malaysia, Bangi, Selangor, Malaysia.
- State Key Laboratory of Systems Medicine for Cancer, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
ORCID-Profile: Michelle Yee Mun Teo
Förderung
- Ministry of Higher Education, Malaysia
- UCSI University https://www.ucsiuniversity.edu.my/about-us/research
Zitieren
APA
Arshad, N. F., Nordin, F. J., Foong, L. C., In, L. L. A., & Teo, M. Y. M. (2024). Engineering receptor-binding domain and heptad repeat domains towards the development of multi-epitopes oral vaccines against SARS-CoV-2 variants. PLOS ONE. https://doi.org/10.1371/journal.pone.0306111
Vancouver
Arshad NF, Nordin FJ, Foong LC, In LLA, Teo MYM. Engineering receptor-binding domain and heptad repeat domains towards the development of multi-epitopes oral vaccines against SARS-CoV-2 variants. PLOS ONE. 2024. doi:10.1371/journal.pone.0306111
BibTeX
@article{Arshad2024,
author = {Arshad, Nur Farhanah and Nordin, Fariza Juliana and Foong, Lian Chee and In, Lionel Lian Aun and Teo, Michelle Yee Mun},
title = {Engineering receptor-binding domain and heptad repeat domains towards the development of multi-epitopes oral vaccines against SARS-CoV-2 variants},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0306111}
}
EUVIMED